Emirati Genome Program expands to include key facilities across Burjeel Hospital’s network in Abu Dhabi

27
  • Five additional collection sites managed by Burjeel Hospital’s dedicated medical team have been added to the Emirati Genome Program
  • The collaboration follows the Department of Health’s guidance to integrate healthcare facilities and increase collection sites across the Emirate of Abu Dhabi

United Arab Emirates, Abu Dhabi: The Emirati Genome Program expanded its reach with new sample collection centres that have been added through dedicated facilities across Burjeel Hospital’s network in Abu Dhabi. The announcement, which was made during an attended by senior officials and healthcare professionals from Burjeel Hospital as well as G42 Healthcare, marks the beginning of important scientific collaborations between the two organizations.

As part of the new partnership, citizens in the Emirate can now participate in the program by visiting Burjeel Medical City – MBZ City, Burjeel Oasis Medical Centre – Madinat Zayed, Burjeel Medical Centre – Deerfields Mall, Burjeel Medical Centre at Al Shamkha or Burjeel Royal Hospital, Al Ain.

During the event, prominent healthcare professionals including Dr. Humaid Al Shamsi, Director of Burjeel Cancer Institute ( BCI ) & VPS Oncology at VPS Healthcare and Head of the Emirates Oncology Society, Dr. Rihan Saafan, Head of Obstetrics and Gynecology and Dr. Zainul AabideenHead of Paediatric, and Paediatric Haematology and Oncology at Burjeel Medical City shed light on the value and impact of genomics on the transformation of healthcare by tailoring patients’ management plans to deliver more personalized medical care.

John Sunil, Regional CEO Burjeel Group Abu Dhabi & Al Ain Region, VPS Healthcare, said, “We are excited to become part of such key national programs that are set to transform healthcare in Abu Dhabi and deliver on its vision of establishing the Emirate as a hub for medical research and innovation. We encourage all Emiratis to participate in the Emirati Genome Program, which is focused on delivering better insights into genetic variations of the local population that will ultimately support positive patient outcomes on the long run. All our centers are equipped with best-in-class medical and support services delivered by well-trained, accredited, and skilled professionals to facilitate ease of participation in the program.”

The Emirati Genome Program aims to provide preventive and personalized healthcare for the Emirati population. This is achieved by understanding citizens’ genetic makeup to deliver the next wave of key innovations that holds the promise for a healthier local community now and for future generations.

On his part, Ashish Koshy, CEO of G42 Healthcare said, “The Emirati Genome Program is designed to enable precise and customized medical treatment that will support a more robust healthcare system in the UAE. We are pleased to see partnerships extending beyond public entities to private healthcare businesses. With this strategic collaboration, we are looking forward to raising awareness amongst the citizens to better understand the positive impact and relevance of genetics to their lives. Through Burjeel’s extensive network, we will be able to provide easier access for more volunteers to participate in the program.”

Details of the Emirati Genome Program, including complete participation information, can be found at www.emiratigenomeprogram.ae or by calling 800 UAE GENOME.

About the Emirati Genome Program

The Emirati Genome Program (EGP) is the world’s first dedicated program to ever study the Arab genome. This initiative is a strategic public-private partnership between Department of Health, Abu Dhabi, and G42 Healthcare to refine the de novo Emirati reference genome with the intention of transforming the UAE healthcare to preventive systems and future proof the health of the nation.  G42 Healthcare, the leading Abu Dhabi based HealthTech company that was responsible for setting up one of the world’s largest testing and diagnostics laboratory to fight the COVID-19 pandemic, and for conducting the world’s first Pan Arab clinical trials for COVID-19 inactivated vaccine, has established a state-of-the-art research and innovation hub at OMICS Center of Excellence in Masdar City. The Emirati Genome Program (EGP) has already referenced the Emirati genome based on DNA samples from 1,000 UAE nationals using cutting edge next and third generation sequencing with artificial intelligence, and now extending the study to the wider Emirati population, making EGP the most ambitious genomic program worldwide.

G42 Healthcare

G42 Healthcare, a leading health-tech company, is on a mission to develop a world-class healthcare sector in the UAE and beyond, by harnessing data and advanced medical technologies to unlock the potential of personalized and preventive care and transforming the traditional healthcare ecosystem.

At the forefront in the battle against COVID-19, we have established Biogenix Labs, UAE’s first COVID-19 accredited large-scale throughput laboratory, facilitated the 4Humanity clinical trials, the world’s first phase three trial for inactivated vaccine against COVID-19 with over 43,000 volunteers from 125+ nationalities across the pan-Arab region, supported UAE’s healthcare authorities on the national vaccination implementation, employed advanced AI techniques and vast computing resources to accelerate the detection of COVID-19, conducted research into new vaccines and drug therapies, and built Omics Centre of Excellence, the region’s largest and most technologically advanced omics facility that is the backbone for the Emirati Genome Program, the world’s most comprehensive population genomics initiative.

Beyond COVID-19 we have plans and R&D encompassing genomics, imaging and diagnostics, digitization programs, to support the health of future generations. At G42 Healthcare, our plans are large in scale and bold in ambition. We partner extensively with governments, leading international entities, scientists and researchers and the wider medical community who subscribe to our values and our mission as we develop solutions to future-proof the health of nations.

About Burjeel Hospital:

Burjeel Hospital is Abu Dhabi’s premier private healthcare facility providing world-class, specialized and superior healthcare complemented by a warm and personalized human touch to the growing population of the emirate of Abu Dhabi.

A unit of the VPS Healthcare, Burjeel Hospital opened for patients in April 2012 as a Tertiary hospital under the auspices of the Health Authority for Abu Dhabi. At the core of the organization is a team of exceptionally skilled and highly experienced health professionals, collaborating as multidisciplinary teams with Guests and their families as the main focus, to provide the best healthcare experience.

Burjeel Hospital received the prestigious Joint Commission International (JCI) accreditation in June 2013 – 15 months after starting operations. Currently, the hospital is affiliated with some of the world’s best healthcare institutions for its centers of excellence and is now becoming a renowned center of referral for Cardiovascular, Orthopedics, Ophthalmology, Pediatrics, Obstetrics and Gynaecology, Reproductive Medicine and many more specialties handling complex laparoscopic and minimally invasive surgeries.

The hospital has full-fledged pharmacy, laboratory, and radiology units to serve Guests at any time of the day. Burjeel also houses a restaurant and a coffee shop, serving the finest and healthiest cuisines from across the world. Combining all-round specialization and expertise with most advanced technology, Burjeel offers the best in diagnostic, curative, as well as preventive aspects of healthcare.